Q4 2016 13F Holders as of 12/31/2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
227
-
Total 13F shares, excl. options
-
84.4M
-
Shares change
-
-1.33M
-
Total reported value, excl. options
-
$3.27B
-
Value change
-
-$80.5M
-
Put/Call ratio
-
1.24
-
Number of buys
-
112
-
Number of sells
-
-114
-
Price
-
$38.70
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q4 2016
283 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q4 2016.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 227 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 84.4M shares
of 99.6M outstanding shares and own 84.71% of the company stock.
Largest 10 shareholders include FMR LLC (13M shares), VANGUARD GROUP INC (6.44M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.98M shares), PERCEPTIVE ADVISORS LLC (3.32M shares), BB BIOTECH AG (3.15M shares), Invesco Ltd. (2.78M shares), FRANKLIN RESOURCES INC (2.41M shares), JANUS CAPITAL MANAGEMENT LLC (2.36M shares), STATE STREET CORP (2.29M shares), and BlackRock Institutional Trust Company, N.A. (2.27M shares).
This table shows the top 227 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.